9/25, 2023 Recanemab has been approved by the MHLW for the treatment of Alzheimer's disease; will O-Force's short peptide (JAL-TA9) in development be a safer and cheaper fundamental treatment beyond recanemab?

December 23, 2023 Last updated : January 7, 2024 admin

The short peptide we are developing (JAL-TA9) is expected to be used as a safe and inexpensive fundamental treatment for AD beyond lecanemab, as shown in the table below.

Categories
Alzheimer

Leave a Reply

Your email address will not be published. Required fields are marked *

Next article
4/19, 2023 Nakamura et al. at O-Force LLC have shown that short peptides (GSGNR, GSGFK) prevent the aggregation of amyloid-β, which causes Alzheimer's disease, and improve memory impairment in a mouse model of the disease.
December 31, 2023